Copper chelation in cancer therapy using tetrathiomolybdate: An evolving paradigm

Expert Opinion on Investigational Drugs

Volumn 18, Issue 4, 2009, Pages 541-548

  Khan, Gazala ^a   Merajver, Sofia ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Angiogenesis; Breast cancer; Cancer chemotherapy; Cancer prevention; Copper chelation; Head and neck cancer; NF B; Renal cell cancer; Tetrathiomolybdate

Indexed keywords

COPPER; FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; TETRATHIOMOLYBDIC ACID;

ANEMIA; ANTIANGIOGENIC ACTIVITY; BEDTIME DOSAGE; BREAST CANCER; CANCER CHEMOTHERAPY; CERULOPLASMIN BLOOD LEVEL; CHELATION THERAPY; COLON CANCER; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HEAD AND NECK CARCINOMA; HUMAN; KIDNEY CARCINOMA; LEUKOPENIA; NEUTROPENIA; NONHUMAN; REVIEW; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; WILSON DISEASE;

ANIMALS; ANTINEOPLASTIC AGENTS; CHELATING AGENTS; COPPER; HEPATOLENTICULAR DEGENERATION; HUMANS; MOLYBDENUM; NEOPLASMS;

EID: 67649610311     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780902845622     Document Type: Review

References (58)

1. Klagsbrun M, Knighton D, Folkman J. Tumor angiogenesis activity in cells grown in tissue culture. Cancer Res 1976;36(1):110-114
2. Folkman J. Tumor angiogenesis.Adv Cancer Res 1974;19(0):331-358
3. Holleb AI, Folkman J. Tumor angiogenesis. CA Cancer J Clin 1972;22(4):226-229
4. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285(21):1182-1186
5. Naumov GN, Bender E, Zurakowski D, et al. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst 2006;98(5):316-325 (Pubitemid 43338211)
6. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86(3):353-364 (Pubitemid 26272076)
7. Kandel J, Bossy-Wetzel E, Radvanyi F, et al. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 1991;66(6):1095-1104 (Pubitemid 121001400)
8. Folkman J, Hanahan D. Switch to the angiogenic phenotype during tumorigenesis. Princess Takamatsu Symp 1991;22:339-347
9. Fieth C, Kebig A, Mohr K. Angiogenesis inhibitors in cancer therapy. Bevacizumab against colon carcinoma. Pharm Unserer Zeit 2007;36(6):442-445
10. Scott LJ. Bevacizumab: in first-line treatment of metastatic breast cancer. Drugs 2007;67(12):1793-1799 (Pubitemid 47263182)
11. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist 2007;12(3):356-361 (Pubitemid 46556802)
12. de Gramont A, Tournigand C, Andre T, et al. Targeted agents for adjuvant therapy of colon cancer. Semin Oncol 2006;33(6 Suppl 11):S42-5 (Pubitemid 44908570)
13. Diaz-Rubio E. Vascular endothelial growth factor inhibitors in colon cancer. Adv Exp Med Biol 2006;587:251-275
14. Lyseng-Williamson KA, Robinson DM. Spotlight on bevacizumab in advanced colorectal cancer, breast cancer, and non-small cell lung cancer. BioDrugs 2006;20(3):193-195
15. Cascone T, Troiani T, Morelli MP, et al. Antiangiogenic drugs in non-small cell lung cancer treatment. Curr Opin Oncol 2006;18(2):151-155 (Pubitemid 43740435)
16. Kuczyk M, Kruck S, Merseburger AS. Efficacy of multikinase inhibitors in the treatment of advanced renal cell cancer. A snapshot. Urologe A 2007;46(5):504-8, 10 (Pubitemid 46740673)
17. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25(7):884-896 (Pubitemid 350002890)
18. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-124 (Pubitemid 46089672)
19. McKeage K, Wagstaff AJ. Sorafenib: in advanced renal cancer. Drugs 2007;67(3):475-83; discussion 84-85 (Pubitemid 46425553)
20. Strumberg D. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today (Barc) 2005;41(12):773-784 (Pubitemid 43333354)
21. Lang L. FDA approves sorafenib for patients with inoperable liver cancer. Gastroenterology 2008;134(2):379 (Pubitemid 351173079)
22. Brewer GJ, Merajver SD. Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper-a review. Integr Cancer Ther 2002;1(4):327-337 (Pubitemid 37107843)
23. Miller RF, Engel RW. Interrelations of copper, molybdenum and sulfate sulfur in nutrition. Fed Proc 1960;19:666-671
24. CF MI, El-Gallad TT, Bremner I, Weham G. Copper and molybdenum absorption by rats given ammonium tetrathiomolybdate. J Inorg Biochem 1981;14(2):163-175 (Pubitemid 11120306)
25. Clarke NJ, Laurie SH. The copper-molybdenum antagonism in ruminants. I. The formation of thiomolybdates in animal rumen. J Inorg Biochem 1980;12(1):37-43
26. Weber KM, Leaver DD, Wedd AG. The behaviour of thiomolybdates in in vitro systems. Br J Nutr 1979;41(2):403-405 (Pubitemid 9130827)
27. Marcilese NA, Ammerman CB, Valsecchi RM, et al. Effect of dietary molybdenum and sulfate upon copper metabolism in sheep. J Nutr 1969;99(2):177-183
28. Mills CF, Monty KJ, Ichihara A, Pearson PB. Metabolic effects of molybdenum toxicity in the rat. J Nutr 1958;65(1):129-142
29. Joyce DA, Wade DN, Swanson BR. The pharmacokinetics of albumin conjugates of D-penicillamine in rats. Drug Metab Dispos 1989;17(2):208-211 (Pubitemid 19083607)
30. Joyce DA. D-penicillamine pharmacokinetics and pharmacodynamics in man. Pharmacol Ther 1989;42(3):405-427 (Pubitemid 19180716)
31. Brewer GJ. Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis and inflammation. J Cell Mol Med 2003;7(1):11-20 (Pubitemid 37123372)
32. Vine AK, Brewer GJ. Tetrathiomolybdate as an antiangiogenesis therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration. Trans Am Ophthalmol Soc 2002;100:73-6; discussion 6-7 (Pubitemid 37039358)
33. Brewer GJ, Dick RD, Yuzbasiyan-Gurkin V, et al. Initial therapy of patients with Wilson's disease with tetrathiomolybdate. Arch Neurol 1991;48(1):42-47
34. Lee VE, Schulman JM, Stiefel EI, et al. Reversible precipitation of bovine serum albumin by metal ions and synthesis, structure and reactivity of new tetrathiometallate chelating agents. J Inorg Biochem 2007;101(11):1707-1718 (Pubitemid 47576218)
35. Song M, Song Z, Barve S, et al. Tetrathiomolybdate protects against bile duct ligation-induced cholestatic liver injury and fibrosis. J Pharmacol Exp Ther 2008;325(2):409-416 (Pubitemid 351574799)
36. Zhou H, Fischer HP. Hereditary hemochromatosis, alpha-1-antitrypsin deficiency and Wilson's disease : pathogenesis, clinical findings and pathways to diagnosis. Pathologe 2008;29(1):73-83
37. Machado AA, Deguti MM, Genschel J, et al. Neurological manifestations and ATP7B mutations in Wilson's disease. Parkinsonism Relat Disord 2008;14(3):246-249
38. Sinha S, Taly AB. Withdrawal of penicillamine from zinc sulphate-penicillamine maintenance therapy in Wilson's disease: promising, safe and cheap. J Neurol Sci 2008;264(1-2):129-132 (Pubitemid 350184085)
39. Brewer GJ. Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's disease. Exp Biol Med (Maywood) 2001;226(7):665-673 (Pubitemid 32619605)
40. Karunajeewa H, Wall A, Metz J, Grigg A. Cytopenias secondary to copper depletion complicating ammonium tetrathiomolybdate therapy for Wilson's disease. Aust N Z J Med 1998;28(2):215-216 (Pubitemid 28218859)
41. Brewer GJ. Interactions of zinc and molybdenum with copper in therapy of Wilson's disease. Nutrition 1995;11(1 Suppl):114-116
42. Brewer GJ, Dick RD, Johnson V, et al. Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients. Arch Neurol 1994;51(6):545-554
43. Walshe JM. Thiomolybdates in the treatment of Wilson's disease. Arch Neurol 1992;49(2):132-133
44. Ziche M, Gullino PM. Angiogenesis and neoplastic progression in vitro. J Natl Cancer Inst 1982;69(2):483-487 (Pubitemid 12018601)
45. Ziche M, Jones J, Gullino PM. Role of prostaglandin E1 and copper in angiogenesis. J Natl Cancer Inst 1982;69(2):475-482 (Pubitemid 12018600)
46. Khan GN, Merajver SD. Modulation of angiogenesis for cancer prevention: strategies based on antioxidants and copper deficiency. Curr Pharm Des 2007;13(35):3584-3590 (Pubitemid 350238929)
47. Hassouneh B, Islam M, Nagel T, et al. Tetrathiomolybdate promotes tumor necrosis and prevents distant metastases by suppressing angiogenesis in head and neck cancer. Mol Cancer Ther 2007;6(3):1039-1045 (Pubitemid 46554574)
48. Pan Q, Kleer CG, van Golen KL, et al. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res 2002;62(17):4854-4859 (Pubitemid 34984403)
49. Pan Q, Bao LW, Kleer CG, et al. Antiangiogenic tetrathiomolybdate enhances the efficacy of doxorubicin against breast carcinoma. Mol Cancer Ther 2003;2(7):617-622
50. Pan Q, Bao LW, Merajver SD. Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NFkappaB signaling cascade. Mol Cancer Res 2003;1(10):701-706 (Pubitemid 37025588)
51. Brewer, GJ, Johnson V, Dick RD, Kluin KJ, et al. treatment of Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 1996;53:1017-1025
52. Brewer GJ, Ullenbruch MR, Dick R, et al. Tetrathiomolybdate therapy protects against bleomycin-indcued pulmonary fibrosis in mice. J Lab Clin Med 2003;141:210-216 (Pubitemid 36324239)
53. Brewer GJ, Dick RD, Grover DK, et al. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clin Cancer Res 2000;6(1):1-10 (Pubitemid 30064969)
54. Henry NL, Dunn R, Merjaver S, et al. Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer. Oncology 2006;71(3-4):168-175
55. Redman BG, Esper P, Pan Q, et al. Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin Cancer Res 2003;9(5):1666-1672 (Pubitemid 36554589)
56. Gartner EM, Griffith KA, Pan Q, et al. A pilot trial of the anti-angiògenic copper lowering agent tettrathiomolybdate in combination with irnotecan, 5-fluorouracil and leucovorin for metastatic colonc acner. Invest New Drugs 2009;27:159-165
57. Juarez JC, Manuia M, Burnett ME, et al. Superoxide dismutase 1 (SOD1) is essential for H2O2-mediated oxidation and inactivation of phosphatases in growth factor signaling. Proc Natl Acad Sci USA 2008;105(20):7147-7152 (Pubitemid 351754446)
58. Donate F, Juarez JC, Burnett ME, et al. Identification of biomarkers for the antiangiogenic and antitumour activity of the superoxide dismutase 1 (SOD1) inhibitor tetrathiomolybdate (ATN-224). Br J Cancer 2008;98(4):776-783 (Pubitemid 351272612)